证券代码：002294 证券简称：信立泰 编号：2025-036 深圳信立泰药业股份有限公司 第六届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳信立泰药业股份有限公司（下称"公司"）第六届董事会第十二次会议 于 2025 年 6 月 22 日上午 10 时，以通讯及书面方式召开，会议通知于 2025 年 6 月 19 日以电子邮件方式送达。应参加董事 9 人，实际参加董事 9 人，其中，叶 澄海、沈清、刘来平以书面方式出席会议，出席董事符合法定人数。会议由公司 董事长叶宇翔先生主持，本次会议召开符合法律法规和《公司章程》等有关规定。 （具体以工商登记备案为准）；信泰医疗的注册资本将由 11,250 万元增至 11,556.5265 万元（具体以工商登记备案为准）。 本次交易前后，公司合并报表范围未发生变更，信泰医疗、巴特勒均为公司 合并报表范围内的控股子公司。 与会董事审议并形成如下决议： 一、会议以 9 人同意，0 人反对，0 人弃权，审议通过了《关于子公司信泰 医疗收购巴特勒股权及增资的议案》。 为进一步理顺并表子公司的 ...

Group 1 - The core viewpoint of the news is that the ICBC Frontier Medical Stock C (010685) has experienced a decline of 1.24% on June 19, with a cumulative drop of 8.33% over the last five trading days, and its latest net value is 2.94 yuan [1] - The fund was established in November 2020, with a total fund size of 1.38 billion yuan, and has recorded a cumulative return of -10.43% since inception [1] - As of the end of 2024, institutional investors hold 0.20 million shares, accounting for 3.55% of the total shares, while individual investors hold 5.51 million shares, making up 96.45% of the total [1] Group 2 - The current fund manager, Zhao Bei, has a master's degree and has been with ICBC Credit Suisse since 2010, currently serving as the deputy director of the research department and head of the healthcare research team [2] - Zhao has managed several funds, including the ICBC Healthcare Industry Stock Fund since November 2014 and the ICBC Frontier Medical Stock Fund since February 2016 [2] - As of March 31, 2025, the top ten holdings of ICBC Frontier Medical Stock C account for a total of 59.05%, with major holdings including Heng Rui Medicine (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [2]

今日（6月17日），A股三大指数均收跌，市场全天成交额1.24万亿元，较前一交易日小幅缩量64亿元；收盘 上涨个股超2200只，其中收盘股价涨停的个股有61只。 从概念板块来看，脑机接口涨幅居首，板块内倍益康"30cm"涨停，爱朋医疗"20cm"涨停。此外，还有可燃 冰、页岩气、核污染防治等概念涨幅居前。 下跌方面，重组蛋白和减肥药概念均跌超2%，创新药、短剧游戏、CRO等概念板块跌幅居前。 17股收盘价创历史新高 不含近一年上市的次新股，今日共有17股收盘价创历史新高。从行业属性来看，汽车、计算机、基础化工行 业创新高的个股较为集中，均有2股出现在名单中。 收盘价创历史新高股中，今日股价平均上涨5.36%，涨停的有倍益康，涨幅居前的有中寰股份、盛帮股份、若 羽臣等。 4股获北向资金龙虎榜逆市净买入 今日龙虎榜中，共13股获机构净买入超千万元，萃华珠宝（维权）获机构净买入5546.94万元，居首；其次是 赢合科技（维权）、通源石油，均获净买入超4000万元。 机构净卖出个股中，哈尔斯遭机构净卖出5839.97万元，居首；其次是招商南油、信立泰，分别遭净卖出 5327.4万元、5184.34万元。 | | | ...

Core Viewpoint - On June 17, the Shanghai Composite Index fell by 0.04%, with institutional investors appearing on the trading lists of 34 stocks, net buying 16 and net selling 18 stocks [1][2]. Institutional Trading Summary - The stock with the highest net buying by institutional seats was Cuihua Jewelry, which closed down by 8.62% with a turnover rate of 27.06% and a transaction amount of 1.021 billion yuan. It was listed on the trading list due to a daily decline deviation of -8.50%, with a total net buying of 55.4694 million yuan from seven institutional seats [2][5]. - Yinghe Technology closed at the daily limit, up by 20.01%, with a turnover rate of 11.67% and a transaction amount of 1.461 billion yuan. It was listed due to a daily price increase of 20.00%, with a total net buying of 47.4684 million yuan from two institutional seats [2][5]. - Tongyuan Petroleum closed up by 15.98%, with a turnover rate of 61.00% and a transaction amount of 2.264 billion yuan. It was listed due to a turnover rate of 61.00% and a daily price fluctuation of 30.94%, with a total net buying of 41.1007 million yuan from three institutional seats [2][5]. Market Performance Analysis - The average increase of stocks with net buying by institutions was 8.43%, outperforming the Shanghai Composite Index. Notable performers included Chuangshi Technology and Beilu Pharmaceutical, which closed at the daily limit [3]. - A backtest of stocks with net buying by institutions over the past month showed a 51.07% probability of an increase the next day, and a 49.79% probability of outperforming the Shanghai Composite Index. The probability of an increase within three days after being listed was 44.21% [3]. Net Selling Analysis - The stock with the highest net selling by institutions was Hars, which was listed due to a daily decline deviation of -9.88%, with a total net selling of 58.3997 million yuan from two institutional seats [3][6]. - Zhaoshang Nanyou was listed due to a daily increase deviation of 10.11%, with a total net selling of 53.2740 million yuan from one institutional seat [3][6]. Deep and Shanghai Stock Connect Summary - On June 17, 12 stocks on the trading list had appearances from Deep and Shanghai Stock Connect, with net buying in Yinghe Technology, Xintai, and Taihe shares, amounting to 28.2691 million yuan, 9.8550 million yuan, and 5.8624 million yuan respectively [7][9]. - Stocks with net selling included Hengbao shares, Rongfa Nuclear Power, and Gongchuang Turf, with net selling amounts of 104 million yuan, 41.5957 million yuan, and 27.4939 million yuan respectively [7][9].

Group 1 - The A-share market's innovative drug concept stocks have shown strong performance, with the innovative drug sector index reaching a historical high [1] - Notable individual stock performances include Xinghao Pharmaceutical rising over 25%, RuiZhi Pharmaceutical hitting a 20% limit up, and Changshan Pharmaceutical reaching a historical high [1][2] - The overall pharmaceutical sector has experienced a prolonged adjustment period, resulting in low valuations and underweight public holdings, indicating potential for recovery and structural opportunities [2] Group 2 - Specific stock performances include: - Xinghao Pharmaceutical: 25.82% increase, market cap of 3.045 billion [2] - RuiZhi Pharmaceutical: 19.98% increase, market cap of 5.801 billion [2] - Changshan Pharmaceutical: 19.97% increase, market cap of 47.9 billion [2] - Shutaishen: 12.12% increase, market cap of 15.6 billion [2] - The report from China Galaxy Securities suggests that the pharmaceutical market is expected to see continuous recovery and that innovative drug companies will benefit from policy support and improved payment conditions by 2025 [2]

Group 1: Innovation Drug Sector Performance - The Innovation Drug ETF (560900) increased by 3.86%, with a turnover of 9.64% and a transaction volume of 3.1137 million yuan [1] - The CSI Innovation Drug Industry Index (931152) rose by 3.77%, with notable increases in constituent stocks such as Baili Tianheng (688506) up by 10.71%, Zhongsheng Pharmaceutical (002317) up by 9.99%, and BeiGene (688235) up by 8.14% [1] - The ADA conference is highlighted as a significant platform for Chinese innovative drug companies to showcase their GLP-1 research capabilities, potentially boosting the GLP-1 industry chain [1] Group 2: Investment Opportunities in Technology - Morgan Asset Management is integrating its "Global Vision Investment Technology" product line to assist investors in identifying quality technology companies globally amid a new wave of AI-driven technological advancements [2] - The actively managed Morgan Emerging Power Fund aims to capture emerging industry trends, while the Morgan Smart Connectivity Fund focuses on opportunities in the AI sector [2] - The Morgan Pacific Technology Fund selects quality technology companies in the Pacific region, indicating a strategic focus on high-growth sectors [2] Group 3: Passive Investment Products - The Morgan Hang Seng Technology ETF (QDII) allows for easy exposure to Hong Kong tech assets, while the Morgan CSI Innovation Drug Industry ETF (560900) provides access to Chinese innovative drug companies [3] - The Morgan NASDAQ 100 Index Fund (QDII) offers a straightforward way to invest in global technology leaders [3]

Group 1 - The core viewpoint of the news highlights the recent surge in the rare earth permanent magnet sector, driven by export control measures and market dynamics [1][2] - The A500 Index ETF (159351) has shown a positive performance, with a 0.62% increase and a trading volume exceeding 2 billion yuan, indicating strong investor interest [1][2] - The rare earth industry is experiencing a supply tightening and price stabilization, with expectations for moderate price increases benefiting equity sector profitability [2] Group 2 - The A500 Index ETF closely tracks the CSI A500 Index, which includes 500 representative stocks across various industries, balancing large-cap stocks with core industry leaders [2] - The A-share market is seen as having the potential for a bull market, driven by increasing household asset allocation towards equities and improvements in corporate governance and shareholder returns [3] - The overall profitability of Chinese enterprises is expected to rise, with a historical supply clearing cycle anticipated, indicating a shift towards higher value sectors [3]

证券代码：002294 证券简称：信立泰 编号：2025-035 深圳信立泰药业股份有限公司 关于阿利沙坦酯吲达帕胺缓释片（复立安®） 获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，深圳信立泰药业股份有限公司（下称"公司"）收到国家药品监督管 理局核准签发的阿利沙坦酯吲达帕胺缓释片（复立安®）药品注册证书。现就相 关信息公告如下： 一、药品基本信息 药品通用名：阿利沙坦酯吲达帕胺缓释片 剂型：片剂 规格：每片含阿利沙坦酯 240mg 与吲达帕胺 1.5mg 适应症：原发性高血压 注册分类：化学药品 2.3 类 上市许可持有人：深圳信立泰药业股份有限公司 药品批准文号：国药准字 H20250028 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二〇二五年六月五日 二、其他相关说明 阿利沙坦酯吲达帕胺缓释片（复立安®）用于治疗原发性高血压。复立安®为 国产原研 ARB/利尿剂类复方缓释制剂（项目代码：SAL0108），阿利沙坦酯和 吲达帕胺两药联用，可以降低 ...

Core Viewpoint - The company, Xinlitai (002294), has received approval from the National Medical Products Administration for the registration of Aliskiren Indapamide Sustained-Release Tablets (Fuli'an), which are intended for the treatment of primary hypertension [1] Group 1: Product Details - The new drug contains 240mg of Aliskiren and 1.5mg of Indapamide per tablet [1] - Fuli'an is a domestically developed compound sustained-release formulation combining ARB and diuretics [1] Group 2: Strategic Positioning - The introduction of Fuli'an complements existing products such as Xinlitai, Xinchao, and Fulitai, enhancing the company's competitive edge in the cardiovascular chronic disease treatment sector [1] - The product aims to meet a broader range of clinical needs, thereby strengthening the company's market position [1]

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, specifically for pharmaceutical manufacturing and pharmaceutical services [1][2]. Core Insights - Continuous attention is recommended for innovative drugs with rising prosperity, as evidenced by the record number of 73 oral reports on Chinese innovative drug assets at the 2025 ASCO annual meeting [2][36]. - The Chinese innovative drug sector is experiencing a significant demand from multinational corporations (MNCs), which is reflected in the increasing number of overseas business development (BD) transactions [36]. - The pharmaceutical sector outperformed the market in May 2025, with the SW Pharmaceutical and Biological sector rising by 6.4%, ranking first among Shenwan's primary industries [15][37]. Summary by Sections Investment Highlights - The report highlights a portfolio of A-Shares including Jiangsu Heng Rui Medicine, Huadong Medicine, Sichuan Kelun Pharmaceutical, and others, indicating a focus on companies with strong growth potential [2][5]. - The report notes that the pharmaceutical sector's premium level relative to all A-Shares is currently at a normal level, with a relative premium rate of 87.88% as of the end of May 2025 [28][37]. Performance Analysis - In May 2025, the pharmaceutical sector's performance was ranked first, with individual stock gains led by Staidson Beijing BioPharmaceuticals (+145.4%) and Sunshine Guojian Pharmaceutical (+99.4%) [15][37]. - The report also details the performance of the Hong Kong and U.S. pharmaceutical sectors, noting that the Hong Kong stock pharmaceutical sector outperformed the market while the U.S. sector underperformed [38]. Market Trends - The report emphasizes the upward trend in the innovative drug market, with traditional pharmaceutical companies emerging from centralized procurement challenges and entering a phase of profitability [36]. - The report indicates that the biopharmaceutical sector's sub-sectors, such as chemical raw materials and biological products, have shown strong performance, with increases of 10.5% and 7.3% respectively [20][37].